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ABSTRACT 
 Changes in the human environment, behavior, and lifestyle are 
contributing to the upsurge in the incidence of diabetes. However, better 
management has resulted in a longer survival of patients with diabetes, but it is 
accompanied by long-term chronic complications due to hyperglycemia. 
Individuals with diabetes most often die of cardiovascular disease (CVD) rather 
than from a cause uniquely related to diabetes, such as ketoacidosis or 
hypoglycemia. Diabetic patients have a twofold to six fold higher incidence of 
cardiovascular disease than nondiabetic population. Furthermore, diabetic patients 
with CVD sustain a worse prognosis for survival than CVD patients without 
diabetes and their quality of life also depreciates .Therefore, diabetes has been 
considered as having a risk equivalent to a nondiabetic patient with preexisting 
heart disease. Identification of patients at risk for CVD could felicitate the 
prevention or retardation of cardiovascular events. The management of CVD 
prevention and the problem associated with it needs intensified monitoring by 
pharmacist. 
 The study was carried out the department of Cardiology and General 
Medicine to assess the risk factors of cardiovascular disease in type 2 DM patients 
in the study population. The result reveals that total of 103 diabetic patients 73% 
were diagnosed with CVD and 30% were non CVD. The 10 year risk factors were 
assessed by Framingham risk score for non CVD population. It was found that 
63.33% patients were having >20 % of risk and 26.66 % patients had 10-20% risk 
for future CVD  
  The total number of drugs prescribed for the CVD patients 315 in which, 
the most frequently prescribed was anticoagulants (41.90%), followed by 
dyslipidemic agents (17.77%), antianginals (9.84%). CVD prevention categorized 
into primary and secondary there were 30 (29.1%) patients were provided with 
primary prevention and 73 (70.87%) patients received secondary prevention for 
CVD. 
 The result reveals that continuous monitoring should be done for the 
patients who were taking aspirin and clopidogrel for a prolonged period because 
of chance of resistance. Guidelines are prepared to monitor and manage CVD 
prevention therapy with aspirin and clopidogrel. 
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INTRODUCTION 
 Cardiovascular disease (CVD) is the leading cause of ill-health and 
mortality in people with type two diabetes (T2DM).Type two DM is associated 
with twice the risk of incident coronary heart disease (CHD) and ischemic stroke 
and 2–4 times increased risk of CHD and stroke mortality compared with 
diabetes-free individuals.1 Changes in the human environment, behavior, and 
lifestyle are contributing to the upsurge in the incidence of diabetes. However, 
better management has resulted in a longer survival of patients with diabetes, but 
it is accompanied by long-term chronic complications due to hyperglycemia  
Individuals with diabetes most often die of cardiovascular disease (CVD) rather 
than from a cause uniquely related to diabetes, such as ketoacidosis or 
hypoglycemia2 . Diabetic patients have a twofold to six fold higher incidence of 
cardiovascular disease than non-diabetic population. Furthermore, diabetic 
patients with CVD sustain a worse prognosis for survival than CVD patients 
without diabetes and their quality of life also depreciates. Therefore, diabetes has 
been considered as having a risk equivalent to a non-diabetic patient with 
preexisting heart disease. Identification of patients at risk for CVD could felicitate 
the prevention or retardation of cardiovascular events.3 
DIABETIC HEART DISEASE 4 
 The term "diabetic heart disease" (DHD) refers to heart disease that 
develops in people who have diabetes. Compared with people who don't have 
diabetes, people who have diabetes: 
 Are at higher risk for heart disease 
 Have additional causes of heart disease 
 May develop heart disease at a younger age 
 May have more severe heart disease  
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CAUSES OF DIABETIC HEART DISEASE 5 
 At least four complex processes, alone or combined, can  
lead to diabetic heart disease (DHD). They include 
coronary atherosclerosis; metabolic syndrome; insulin resistance in people who 
have type 2 diabetes; and the interaction of coronary heart disease (CHD), high 
blood pressure, and diabetes. 
1) Coronary Atherosclerosis 6 
 Atherosclerosis is a disease in which plaque builds up inside the arteries. 
The exact cause of atherosclerosis isn't known. However, studies show that it is a 
slow, complex disease that may start in childhood. The disease develops faster as 
you age. 
 Coronary atherosclerosis may start when certain factors damage the inner 
layers of the coronary (heart) arteries. These factors include:7 
 Smoking  
 High amounts of certain fats and cholesterol in the blood 
 High blood pressure 
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 High amounts of sugar in the blood due to insulin resistance or 
 diabetes 
 Plaque may begin to build up where the arteries are damaged. Over time, 
plaque hardens and narrows the arteries. This reduces the flow of oxygen-rich 
blood to your heart muscle. 
 Eventually, an area of plaque can rupture (break open). When this 
happens, blood cell fragments called platelets (PLATE-lets) stick to the site of the 
injury. They may clump together to form blood clots. Blood clots narrow the 
coronary arteries even more. This limits the flow of oxygen-rich blood to  heart 
and may worsen angina (chest pain) or cause a heart attack. 
2) Metabolic Syndrome 8 
 Metabolic syndrome is the name for a group of risk factors that raises  risk 
of both CHD and type 2 diabetes. 
The risk factors are: 
 A large waistline (a waist measurement of 35 inches or more for women 
and 40 inches or more for men). 
 A high triglyceride level (or you’re on medicine to treat high 
triglycerides). Triglycerides are a type of fat found in the blood. 
 A low HDL cholesterol level (or you're on medicine to treat low HDL 
cholesterol). HDL sometimes is called "good" cholesterol. This is because 
it helps remove cholesterol from your arteries. 
 High blood pressure (or you’re on medicine to treat high blood pressure). 
 A high fasting blood sugar level (or you're on medicine to treat high blood 
 sugar). 
 It's unclear whether these risk factors have a common cause or are mainly 
related by their combined effects on the heart. 
 Obesity seems to set the stage for metabolic syndrome. Obesity can cause 
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harmful changes in body fats and how the body uses insulin. 
 Chronic (ongoing) inflammation also may occur in people who have 
metabolic syndrome. Inflammation is the body's response to illness or injury. It 
may raise your risk of CHD and heart attack. Inflammation also may contribute to 
or worsen metabolic syndrome. 
 Research is ongoing to learn more about metabolic syndrome and how 
metabolic risk factors interact. 
3) Insulin Resistance in People Who Have Type 2 Diabetes 9 
 Type 2 diabetes usually begins with insulin resistance. Insulin resistance 
means that the body can't properly use the insulin it makes. 
 People who have type 2 diabetes and insulin resistance have higher levels 
of substances in the blood that cause blood clots. Blood clots can block the 
coronary arteries and cause a heart attack or even death. 
4) The Interaction of Coronary Heart Disease, High Blood Pressure, and 
 Diabetes 10 
 Each of these risk factors alone can damage the heart. CHD reduces the 
flow of oxygen-rich blood to your heart muscle. High blood pressure and diabetes 
may cause harmful changes in the structure and function of the heart. 
 Having CHD, high blood pressure, and diabetes is even more harmful to 
the heart. Together, these conditions can severely damage the heart muscle. As a 
result, the heart has to work harder than normal. Over time, the heart weakens and 
isn’t able to pump enough blood to meet the body’s needs. This condition is 
called heart failure. 
 As the heart weakens, the body may release proteins and other substances 
into the blood. These proteins and substances also can harm the heart and worsen 
heart failure. 
SIGNS AND SYMPTOMS OF DIABETIC HEART DISEASE 
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 Some people who have diabetic heart disease (DHD) may have no signs or 
symptoms of heart disease. This is called “silent” heart disease. Diabetes-related 
nerve damage that blunts heart pain may explain why symptoms aren't noticed. 
Thus, people who have diabetes should have regular medical checkups. Tests may 
reveal a problem before they're aware of it. Early treatment can reduce or delay 
related problems. Some people who have DHD will have some or all of the typical 
symptoms of heart disease. Treatment for a heart attack works best when it's given 
right after symptoms occur. 
CORONARY HEART DISEASE11, 12 
 A common symptom of coronary heart disease (CHD) is angina. Angina is 
chest pain or discomfort that occurs if heart muscle doesn't get enough oxygen-
rich blood. Angina may feel like pressure or squeezing chest and also may feel it 
in shoulders, arms, neck, jaw, or back. Angina pain may even feel like indigestion. 
The pain tends to get worse with activity and go away with rest. Emotional stress 
also can trigger the pain. Other CHD signs and symptoms include.13, 14 
 Nausea (feeling sick to your stomach) 
 Fatigue (tiredness),  
 Shortness of breath, 
 Sweating, 
 Light-headedness 
 Weakness. 
 Some people don't realize they have CHD until they have a heart attack. A 
heart attack occurs if a blood clot forms in a coronary artery and blocks blood 
flow to part of the heart muscle. The most common heart attack symptom is chest 
pain or discomfort. Most heart attacks involve discomfort in the center or left side 
of the chest that often lasts for more than a few minutes or goes away and comes 
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back. The discomfort can feel like uncomfortable pressure, squeezing, fullness, or 
pain. The feeling can be mild or severe. Heart attack pain sometimes feels like 
indigestion or heartburn. Shortness of breath may occur with or before chest 
discomfort.15 
            Heart attacks also can cause upper body discomfort in one or both arms, 
the back, neck, jaw, or upper part of the stomach. Other heart attack symptoms 
include nausea, vomiting, light-headedness or sudden dizziness, breaking out in a 
cold sweat, sleep problems, fatigue, and lack of energy.16 
                 Some heart attack symptoms are similar to angina symptoms. Angina 
pain usually lasts for only a few minutes and goes away with rest. Chest pain or 
discomfort that doesn't go away or changes from its usual pattern (for example, 
occurs more often or while you're resting) can be a sign of a heart attack.17 
 Diabetes-related nerve damage can interfere with pain signals in the body. 
As a result, some people who have diabetes may have heart attacks without 
symptoms. 
HEART FAILURE 18 
 The most common symptoms of heart failure are shortness of breath or 
trouble breathing, fatigue, and swelling in the ankles, feet, legs, abdomen, and 
veins in your neck. As the heart weakens, heart failure symptoms worsen. People 
who have heart failure can live longer and more active lives if the condition is 
diagnosed early and they follow their treatment plans.  
DIABETIC CARDIOMYOPATHY 
 Diabetic cardiomyopathy may not cause symptoms in its early stages. 
Later, may have weakness, shortness of breath, a severe cough, fatigue, and 
swelling of the legs.19 
RISK FACTORS FOR CVD 20 
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 Changes in the human environment, behaviour, and lifestyle are 
contributing to the upsurge in the incidence of diabetes. However, better 
management has resulted in a longer survival of patients with diabetes, but it is 
accompanied by long-term chronic complications due to hyperglycemia. 
Individuals with diabetes most often die of cardiovascular disease (CVD) rather 
than from a cause uniquely related to diabetes, such as ketoacidosis or 
hypoglycemia. Diabetic patients have a twofold to sixfold higher incidence of 
cardiovascular disease than nondiabetic population. Furthermore, diabetic patients 
with CVD sustain a worse prognosis for survival than CVD patients without 
diabetes and their quality of life also depreciates. Therefore, diabetes has been 
considered as having a risk equivalent to a nondiabetic patient with preexisting 
heart disease. Identification of patients at risk for CVD could felicitate the 
prevention or retardation of cardiovascular events. Lifetime risk estimates provide 
a simple conceptual basis for estimating the absolute risk of developing disease 
over the remaining lifespan. Presence of several risk factors among diabetic 
patients suffering from cardiovascular disease stresses on the assessment of the 
individual’s total burden of risk rather than on the level of any particular risk 
factor. Several multivariate risk prediction algorithms have been developed to 
predict future CVD risk but their use has lagged in primary care. 
Risk factors are classified into two types 21 
 
 Traditional risk factors  
1. High blood pressure 
2. Abnormal cholesterol and triglycerides 
3. Obesity 
4. Lack of physical activity 
5. Poorly controlled blood sugar 
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6. Smoking 
7. Age 
8. Cardiovascular impact in the gender 
9. Metabolic syndrome 
10. Unhealthy diet 
11. Stress 
 Non traditional risk factors 
1. Insulin resistance and hyperinsuinemia 
2. Microalbuminuria 
3. Haemaatological and thrombogenic factors 
 
TRADITIONAL RISK FACTORS FOR CVD  
1. High blood pressure (hypertension) 
 High blood pressure has long been recognized as a major risk factor for 
cardiovascular disease. Studies report a positive association between hypertension 
and insulin resistance. When patients have both hypertension and diabetes, which 
is a common combination, their risk for cardiovascular disease doubles. 
 
2. Abnormal cholesterol and high triglycerides 
 Patients with diabetes often have unhealthy cholesterol levels including 
high LDL ("bad") cholesterol, low HDL ("good") cholesterol, and high 
triglycerides. This triad of poor lipid counts often occurs in patients with 
premature coronary heart disease. It is also characteristic of a lipid disorder 
associated with insulin resistance called atherogenic dyslipidemia, or diabetic 
dyslipidemia in those patients with diabetes. Learn more about cholesterol 
abnormalities as they relate to diabetes. 
 
3. Obesity22  
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 Obesity is a major risk factor for cardiovascular disease and has been 
strongly associated with insulin resistance. Weight loss can improve 
cardiovascular risk, decrease insulin concentration and increase insulin sensitivity. 
Obesity and insulin resistance also have been associated with other risk factors, 
including high blood pressure. Being overweight or obese raises your risk of heart 
disease and heart attack.  
 
4. Lack of physical activity 23 
 Physical inactivity is another modifiable major risk factor for insulin 
resistance and cardiovascular disease. Exercising and losing weight can prevent or 
delay the onset of type 2 diabetes, reduce blood pressure and help reduce the risk 
for heart attack and stroke. It's likely that any type of moderate and/or vigorous 
intensity, aerobic physical activity—whether sports, household work, gardening or 
work-related physical activity—is similarly beneficial. 
 
5. Poorly controlled blood sugars (too high) or out of normal range 
 Diabetes can cause blood sugar to rise to dangerous 
levels. Medications may be needed to manage blood sugar. 
 
6. Smoking 
           Smoking puts individuals, whether or not they have diabetes, at higher risk  
for heart disease and stroke. 
7. Age 
          The impact of diabetes on risk of cardiovascular disease appears to diminish 
with advancing age, particularly in women. Although suggestive, this trend can 
not be demonstrated to be statistically significant. It suggests that late onset 
diabetes may have a different effect on the cardiovascular apparatus than early 
onset. 
Introduction 
 
` 
Study on Cardiovascular Risk Factors and its  
Management in  Type 2 Diabetic Patients  10 
8.     Cardiovascular Impact in the gender  
 The relative impact of diabetes was substantially greater for women than 
for men. For each of the cardiovascular diseases morbidity and mortality was 
higher for diabetic women than nondiabetic men. Among those with diabetes, the 
female advantage over men as regards cardiovascular mortality is lost. After 
adjustment for differences in other associated cardiovascular risk factors in the 
two sexes, the relative impact of diabetes on coronary heart disease, peripheral 
vascular disease, or stroke incidence was the same in men and women, but for 
cardiovascular mortality and cardiac failure the impact is still greater in women. 
The reason for the greater susceptibility of women to these cardiovascular 
sequelae of diabetes is not clear. 
9. Matabolic syndrome  
 Metabolic syndrome is the name for a group of risk factors that raises your 
risk of heart disease and type two diabetes. Metabolic syndrome also raises your 
risk of other health problems, such as stroke. 
10. Unhealthy diet 
 An unhealthy diet can raise your risk of heart disease. Foods that are high 
in saturated and trans fats, cholesterol, sodium (salt), and sugar can worsen other 
heart disease risk factors. 
 
11. Stress 
 Stress and anxiety can trigger  arteries to tighten. This can raise  blood 
pressure and  risk of  having a heart attack. Stress also may indirectly raise risk of  
heart disease if it makes  more likely to smoke or overeat foods high in fat and 
sugar. 
NON-TRADITIONAL RISK FACTORS27  FOR CVD 
1) Insulin resistance and hyperinsulinemia 
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 IR is a principal characteristic of T2DM and it develops in multiple organs 
involving the skeletal muscle, liver, adipose tissue and the heart. The onset of 
hyperglycaemia and diabetes is often preceded by several years of IR. Obesity 
plays a major role in this phenomenon and provides an important link between 
T2DM and the accumulation of fat. A significant section of the population with 
T2DM is obese. 
 The hyperinsulinemia, as a result of IR, occurs even before the onset of 
DM, and could be, by chance, related to vascular disease. 
2) Microalbuminuria 
 The term microalbuminuria (MA), a urinary albumin excretion between 30 
and 300 mg/24 h, has been introduced to identify subjects at increased risk of 
early cardiovascular death and progressive renal disease. In individuals with 
T2DM, MA is a prematurely clinical sign suggestive of vascular damage to the 
glomerulus. MA has also been currently reported as an important risk factor for 
CVD and remains the main and most widely used marker of diabetic renal damage 
in clinical practice. It is also a marker of organ dysfunction, and has been 
appeared to be associated with an increased risk of cardiovascular morbidity and 
mortality in T2DM patients. At present, an increased albumin excretion is 
considered to be a renal symptom of generalized endothelial dysfunction. 
According to different studies, the prevalence of MA is up to 19% in T2DM. 
3) Haematological and thrombogenic factors 
 Atherothrombosis, defined as the formation of a thrombus on a pre-
existing atherosclerotic plaque, is the leading cause of mortality in the Western 
world. Diabetes has been recognised as an independent risk factor and 
atherothrombosis accounts for the 80% of deaths in these patients.  It is the result 
of the progression of atherosclerosis, and its major manifestations are sudden 
cardiac death, myocardial infarction, stroke and peripheral arterial ischemia. 
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INTERACTIONS OF TRADITIONAL AND NON-TRADITIONAL RISK 
FACTORS IN DIABETES MELLITUS 
 
 
FRAMINGHAM RISK SCORE 25 
 The FRS is a risk assessment tool that has been derived from data 
collected in the Framingham Heart Study.  The NCEP guidelines recommend that 
patients with two or more risk factors have their FRS calculated. The FRS consists 
of points that are allocated for the various degrees of risk associated with five 
categories: age, total cholesterol level, HDL cholesterol level, tobacco smoking 
status and hypertension (and whether the latter condition is treated). The 
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summation of these points results in a percentage risk of having a cardiac event in 
the next 10 years. Although the Framingham Risk Score (FRS) is the most well 
known risk prediction method for the primary prevention of cardiovascular 
disease, other objective risk assessment options include the Reynold’s Risk Score 
(RRS), high sensitivity C-reactive protein, total number of risk factors, and carotid 
ultrasound to detect atherosclerosis. .  Outline FRS assessment for men and 
women, respectively5. 
 The ATP III treatment algorithm divided patients into 3 risk categories 
based on clinical characteristics and the Framingham 10-year risk score: 
1. Established CHD and CHD risk equivalents: High risk (10-year risk higher  
 than 20%) 
2. Multiple (2 or more) risk factors: Moderately high risk (10-year risk,  
 10% -20%); moderate risk (10-year risk lower than 10%) 
3. Zero to 1 (1 or none) risk factor: Lower risk (10-year risk lower than 10%) 
MANAGEMENT OF CVD PATIENTS HAVING DM 26         
 The ADA (AMERICAN DIABETES ASSOCIATION) and AHA 
(AMERICAN HEART ASSOCIATION) each have been published 
guidelines for CVD prevention.  
 The ADA has issued a separate recommendation for each of the 
cardiovascular risk factors in patients with diabetes, and AHA is shaped 
primary and secondary guidelines that extend to the patients with diabetes. 
 Guidelines for CVD management in diabetes are based on the premise that 
most of the patients with diabetes are at high risk for the future CVD 
events. When diabetes exists in patients with established CVD, absolute 
risk for future events is very high.  
 Even in the absence of CVD, both the ADA, and the AHA identify 
diabetes as a high risk of condition for macrovascular CVD.  
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 Primary prevention can be individually oriented involving screening for 
risk factors and treatment of these risk factors by pharmacological and 
non-pharmacological means so called high risk approach.  
 On the other hand the primary prevention can be directed towards the 
whole population group and secondary prevention is always directed 
towards in individuals.  
PRIMARY PREVENTION OF CVD IN PEOPLE WITH DIABETES27 
Lifestyle management 
 Weight 
 Structured programs that emphasize lifestyle changes such as reduced fat 
(30% of daily energy) and total energy intake and increased regular physical 
activity, along with regular participant contact, can produce long-term weight loss 
on the order of 5–7% of starting weight, with improvement in blood pressure. 
Medical nutrition therapy 
To achieve reductions in LDL cholesterol: 
 Saturated fats should be  7% of energy intake. 
 Dietary cholesterol intake should be  200 mg/day. 
 Intake of trans unsaturated fatty acids should be  1% of energy intake. 
 Physical activity 
 To improve glycemic control, assist with weight loss or maintenance, and 
reduce risk of CVD, at least 150 min of moderate-intensity aerobic physical 
activity or at least 90 min of vigorous aerobic exercise per week is recommended. 
The physical activity should be distributed over at least 3 days per week, with no 
more than 2 consecutive days without physical activity. 
 Blood pressure 
 Blood pressure should be measured at every routine diabetes visit. Patients 
found to have systolic blood pressure 130 mmHg or diastolic blood pressure 80 
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mmHg should have blood pressure confirmed on a separate day. 
 Patients with diabetes should be treated to a systolic blood pressure 130 
 mmHg and a diastolic blood pressure 80 mmHg. 
 
 Lipids 
 In adult patients, test for lipid disorders at least annually and more often if 
needed to achieve goals. In adults under the age of 40 years with low-risk lipid 
values (LDL cholesterol 100 mg/dl, HDL cholesterol 50 mg/dl, and triglycerides  
150 mg/dl), lipid assessments may be repeated every 2 years. 
 Tobacco 
 All patients with diabetes should be asked about tobacco use status at 
 every visit. 
 Every tobacco user should be advised to quit. 
 The tobacco user’s willingness to quit should be assessed. 
 The patient can be assisted by counseling and by developing a plan to quit. 
 
 
 Antiplatelet agents 
 Aspirin therapy (75–162 mg/day) should be recommended as a primary 
prevention strategy in those with diabetes at increased cardiovascular risk, 
including those who are 40 years of age or who have additional risk factors 
(family history of CVD, hypertension, smoking, dyslipidemia, or albuminuria). 
 People with aspirin allergy, bleeding tendency, existing anticoagulant 
therapy, recent gastrointestinal bleeding, and clinically active hepatic disease are 
not candidates for aspirin therapy. Other antiplatelet agents may be a reasonable 
alternative for patients with high risk. 
 Glycemic control 
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 The A1C goal for patients in general is 7%. 
 The A1C goal for the individual patient is an A1C as close to normal (6%) 
as possible, without causing significant hypoglycemia. 
SECONDARY  PREVENTION   OF CVD IN TYPE TWO DM PATIENTS28 
1. Tobacco Exposure should reduce 
2. Lipid Management 
3. Blood pressure  
4. physical activity 
5. weight assessment 
6. Diabetes (HbA1C>7) 
7. Aspirin 
8. Beta blocker  
 
1. Tobacco Exposure 
 Goals: Complete cessation if currently smoking; avoidance of secondhand 
 smoke. 
2. Blood Pressure  
 140/90 mm Hg or 130/80 mm Hg if patient has diabetes or chronic kidney 
disease. Initiate or maintain lifestyle modification—weight control; increased 
physical activity; alcohol moderation. 
 
1. PHYSICAL ACTIVITY 
Everyday Physical Activities 
 Using stairs instead of elevator- Playing actively with children 
 Exercise Options 
  Walking 
 
2. WEIGHT ASSESSMENT 
  BMI Interpretation 
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 <18.5 Underweight 
 18.5-24.9 Normal 
 25.0-29.9 Overweight 
 >30 Obesity 
 30.0-34.9 Obesity I 
 35.0-39.9 Obesity II 
  >40 Obesity III 
 
3. Diabetes  
 Goal: HbA1c < 7%  
4. Aspirin  
 Initiate aspirin, 75 to 325 mg/d, if not contraindicated. 
 
Aspirin Contraindications 
  Hypersensitivity to salicylates or NSAIDs- GI bleeding, unexplained GI 
 blood loss, or hemophilia 
 Use Aspirin with Caution- Anticoagulant use (warfarin/Coumadin) 
  Severe nausea and vomiting or known upper GI 
5. Beta Blockers  
 Start in all post-MI and acute ischemic syndrome patients at 5 to 28 days 
post-MI. Continue indefinitely (previous recommendation was for a minimum of 
six months) Use as needed to manage angina, rhythm or blood pressure 
6. ACE Inhibitors Post-MI  
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 Start as early as 3 days post-MI in stable high-risk patients continue. 
Continue indefinitely for all patients with coronary or other vascular disease 
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American Heart Association (AHA) and American Diabetes Association 
(ADA) Prevention of Cardiovascular Disease in Type 2 Diabetes 2016 
Diabetes Diagnosis   
Diagnostic Criteria for Diabetes and Prediabetes 
 
Diabetes Prediabetes 
HbA1C ≥6.5% 5.7-6.4% 
Fasting glucose ≥126 mg/dL 100-125 mg/dL 
Random glucose ≥200 mg/dL 140-199 mg/dL 
 
 Lifestyle Management   
    •  Lifestyle management is a cornerstone of diabetes clinical care 
    •   It is the primary approach for weight loss 
    •   Lifestyle management includes dietary change, increased energy 
expenditure and behavioral changes (eg, smoking cessation) oduce weight 
loss 
 •  Reduce the need for medication to control CVD risk factors without 
increasing the risk for cardiovascular events  
 
 Pharmacologic Therapy for Weight Management  
    •   Pharmacologic therapy may be considered if lifestyle interventions fail to 
achieve weight  loss goals 
   Pharmacologic Therapy Indications 
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BMI 25-30 kg/m2 with comorbidities 
BMI >30 kg/m2 with or without comorbidities 
 
 
Recommendations for HbA1C Targets  
 HbA1C ≤7.0% for most individuals with type 2 diabetes 
to reduce microvascular disease incidence 
 
 
Blood Pressure Management  
    •   High blood pressure is a major contributor to higher risk for CVD events 
 in individuals with  type 2 diabetes 
 
BP Targets  
BP <140/90 mm Hg for most individuals with type 2 diabetes1,2  
ADA recommends SBP <140 mm Hg for many 
A lower target (<130) may be appropriate for some if it can be achieved safely3   
Pharmacologic therapy should include a 
regimen with an ACEI or ARB (never 
together)3  
If one class is not tolerable, switch to 
the other 
Individuals with CKD should be treated with an ACEI or ARB 
 
 
Cholesterol Management  
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    •   Most individuals with type 2 diabetes have diabetic dyslipidemia 
     •   Elevated triglycerides; decreased HDL-C; elevated, borderline, or normal 
 LDL-C 
    •   LDL-C is the primary target of lipid-lowering therapy 
    •   LDL-C reduction with statins reduces the risk of major CVD events in 
 indiviuals with  or without diabetes 
 
LDL-C Treatment 
Lifestyle changes are the foundation 
Individuals aged 40-75 years with 
diabetes and LDL-C 70-189 mg/dL 
Moderate-intensity statin 
Individuals aged 40-75 years with 
diabetes and ≥7.5% ASCVD risk 
High-intensity statin 
Individuals aged <40 or >75 years with 
diabetes 
Evaluate the benefit of statin therapy 
Evaluate and treat individuals with fasting TG >500 mg/dL 
Aspirin Therapy  
    •   Aspirin therapy for CVD primary prevention in individuals with 
 diabetes is controversial. 
    •   Aspirin reduces CVD events in patients with known CVD (secondary 
 prevention) 
    •   It is effective for primary prevention of myocardial infarction in men 
        The net effect of aspirin therapy depends on baseline risks of CVD and GI 
 bleeding 
Low-
dose 
Reasonable for individuals with a ≥10% 10-year CVD risk and without 
increased bleeding risk 
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aspirin 
(75-162 
mg/d) 
Reasonable for adxults with diabetes who are at intermediate CVD 
risk: 5-10% 10-year CVD risk 
 
PROBLEMS ASSOCIATED WITH MANAGEMENT OF CVD 29 
 Cardiovasvular events are the leading causes of death in diabetic subjects, 
and aspirin is the most frequently used medication for secondary prevention of 
ischemic events in patients with diabetes. However, many patients taking this drug 
eventually have cardiovascular events. Antiplatelet drug resistance has emerged as 
a new concept and is responsible for some of these treatment failures. However, 
not all treatment failures can be attributed to antiplatelet drug resistance. 
 
ASPIRIN CLOPIDOGREL RESISTANCE 30 
 Platelets play a central role in the pathogenesis atherothrombosis .Thus, 
achieving platelet inhibition is an important part of managing those patients who 
suffer from an atherothrombotic event. Low-dose aspirin is effective for 
preventing adverse vascular events in patients suffering with acute coronary 
syndrome stroke and/or peripheral vascular disease. Aspirin alone in many 
instances is not sufficient to prevent ischemic events in the high risk patients 
because aspirin inhibits only the cyclooxygenase pathway and it has no effect on 
the adenosine diphosphate P2Y12 receptor. Dual antiplatelet therapy with 
clopidogrel plus aspirin has been shown to reduce ischemic events in patients with 
unstable angina and MI and especially when they are undergoing percutaneous 
coronary intervention (PCI) and stenting. Despite its proven benefit, the responses 
of individual patients show considerable heterogeneity to aspirin and to 
clopidogrel. The recent data shows that adequate antiplatelet effects are not 
achieved in 5% to 45% of the patients taking aspirin and in 4% to 30% of patients 
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taking clopidogrel, and this suggests that many patients are resistant or partially 
responsive in the drugs’ antiplatelet effect. Thus, measuring the patients’ 
responsiveness to aspirin and clopidogrel may be an important factor in 
monitoring these drugs’ therapeutic efficacy and so improve the cardiovascular 
outcomes. However, there are no clinical guidelines to deal with treatment failure 
for the stent thrombosis and recurrent atherothrombotic events that are due to 
aspirin and clopidogrel resistance. 50% of aspirin resistant population are also 
resistant to clopidogrel. 
 
ROLE OF  PHARMACIST CARDIOVASCULAR DISEASE PREVENTION 
AND MANAGEMENT 31 
 Pharmacists have long undertaken roles in the prevention and management 
of CVD that extend beyond the traditional dispensing of medicines. Evidence can 
now confirm the significant clinical benefits of pharmacist interventions for a 
range of major disease states and preventive health activities related to 
 Diabetes (significant HbA1c reductions) 
 Blood pressure,  
 Smoking cessation,  
 Lifestyle modification, medicines management and medicines adherence. 
 Lipid level monitoring 
 Diet management 
 Assess their 10-year absolute risk using a validated scoring tool derived 
 from the Framingham Heart Study. 
 Check problem associated with management of  CVD 
 .Check the problems associated with duration of therapy 
 Laboratory tests that provide information on clopidogrel or aspirin 
response can aid in the identification of persons who are at risk of 
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experiencing recurrent cardiovascular events. 
 Dosage adjustments  
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LITERATURE REVIEW 
 
1) Julia. et al (2016)32 conducted a study on diabetes treatment and risk of 
heart failure. This study assessed the association between risk of 
cardiovascular disease heart failure and mortality and different diabetic 
drugs in people with type two diabetes. The study concluded that use of 
gliptins or glitazones was associated with decreased risks of heart failure, 
cardiovascular disease, and all cause mortality compared with non-use of 
these drugs.  
2) Eral et al (2005)33 studied on risks for all causes mortality, cardiovascular 
disease and diabetes associated with metabolic syndrome. The study 
concluded that estimate suggest that the population attributable fraction for 
the metabolic syndrome as it currently conceived is 6-7% for all cause 
mortality,12-17% for cardiovascular disease and 30-52% for diabetes. 
Further research is needed to establish the use of metabolic syndrome in 
predicting risk for death, cardiovascular disease and diabetes in various 
population subgroup. 
3) John B et al (2007)34 conducted a study on primary prevention of 
cardiovascular disease in people with DM. The study concluded that life 
style and medical interventions that will prevent the development of CVD 
in people with DM. The study reveled that People with either type 1 or 
type 2 diabetes are at increased risk for CVD and have worse outcomes 
after surviving a CVD event. The aggressive use of lifestyle modifications 
can reduce or delay the need for medical intervention. Appropriate 
lifestyle and medical interventions will reduce the occurrence of CVD and 
allow people with diabetes to live healthier and longer lives. 
 
Literature Review 
 
 
Study on Cardiovascular Risk Factors and its  
Management in  Type 2 Diabetic Patients  26 
4)  Anthony et al (2003)35 conducted a study on secondary prevention of 
cardiovascular events with long term pravastatins in patients with DM. 
The study reveals that cholesterol lowering treatment with pravastatins 
therapy prevents cardiovascular events such as stroke in patients with DM 
established CHD. 
5) Janet K.  et al (2012)36 studied on  hypoglycemia, diabetes, and 
cardiovascular disease. The study reveals that hypoglycemia is a common 
effect of treatment for diabetes and is prevalent among both type one and 
type two patients. Hypoglycemia may acutely increase the risk of CV 
complications, because of reduced blood flow in the heart and electrical 
disturbances leading to arrhythmia and prolonged QT interval. 
6) Komola et al (2014)37 conducted study on cardiovascular safety profile of 
currently available diabetic drugs. The study concluded that careful 
selection of drug therapy paying particular attention to cardiovascular 
safety is important in optimizing diabetic therapy. Thus, treatment and 
management of diabetes should be adjusted on an individual basis based 
on age, duration of diabetes, risk for CVD, and presence of microvascular 
and macrovascular complications 
7) Mary et al (2014)38 carried out study on risk of cardiovascular disease 
among diabetic patients.The study reveled that Primary prevention through 
improved control of risk factors and therapeutic lifestyle modification 
(including dietary modification, aerobic exercise, and smoking cessation). 
8) Arvind et al (2017) 39conducted a study on prevalence of diabetes and 
cardiovascular risk factors in middleclass urban participants in India. The 
study concluded that in the urban Indian middle class, more than a quarter 
of patients with diabetes are undiagnosed and the status of control is low. 
Cardiovascular risk factors—hypertension, hypercholesterolemia, low 
HDL cholesterol, hypertriglyceridemia, and smoking/smokeless tobacco 
use are highly prevalent. There is low awareness, treatment, and control of 
hypertension and hypercholesterolemia in patients with diabetes. 
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9) Iciar et al (2014 )40 conducted a study on type 2 diabetes and 
cardiovascular disease. The study concluded that there are consistent 
evidences that optimal glycaemic control, along with control of 
hypertension, dyslipidaemia, smoking cessation, and weight loss are 
necessary for reducing cardiovascular risk in type two diabetic patients. 
Cardiovascular benefits are obtained if the control of traditional 
cardiovascular risk factors begins early in subjects with short duration of 
DM and low cardiovascular risk. 
10) Haitham  et al (2016)41 conducted a study on prevalence and risk factors 
of clopidogrel non-response among Saudi patients undergoing coronary 
angiography. The study concluded that high rate of clopidogrel in-vitro 
non-response among Saudi patients undergoing coronary angiography. 
11) Chris R et al (2014)42 conducted a study on cardiovascular impact of 
drugs used in the treatment of diabetes. The study concluded that cellular 
basis for the therapeutic action of these drugs, addresses the evidence for 
their cardiovascular benefits and risks. A particular focus is provided on 
metformin as it is the first choice drug for most patients with type two 
diabetes. 
12) Bharti et al (2015)43 performed a study on statin use and risk of diabetes 
mellitus. The authors concluded that that statins have been found to 
increase glycosylated haemoglobin and fasting serum glucose levels. 
statins can have diabetogenic risk, they have more long term benefits 
which can outweigh the risk. In elderly patients and those with metabolic 
syndrome, as the risk of diabetes increase, the statins should be used 
cautiously. Other than a subset of population with risk for diabetes; statins 
still have long term survival benefits in most of the patients.  
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13) Nathan et al  ( 2016)44 conducted a study on cardiovascular risk factor 
targets cardiovascular disease event risk in diabetes The study reported 
that optimal levels of BP,LDL -C,HbA1C occurring together in individuals 
with DM are uncommon but are associated with lower risk of CHD and 
CVD. 
14) Mansour M. et al (2016)45 conducted a study on coronary artery disease 
and diabetes mellitus. The study revealed that an important part of any 
preventive program for CAD should include clear prevention strategies for 
DM and other associated metabolic risk factors, such as obesity. 
Preventive measures, such as physical exercise in high-risk groups, at the 
population level should be encouraged. 
15) Hisao et al (2002)46 conducted a study on low-dose aspirin for primary 
prevention of atherosclerotic events in patients with type 2 diabetes. The 
study concluded that in this study of patients with type two diabetes, low-
dose aspirin as primary prevention did not reduce the risk of 
cardiovascular events. 
16) Derun et al (2010)47 conducted a study on aspirin resistance and its 
associate with glycemic control  in type two diabetes mellitus. The study 
reported that diabetic patients had significantly higher aspirin resistance, 
compared with nondiabetic controls. A correlation analysis revealed that 
aspirin resistance was positively correlated with body mass index, fasting 
blood glucose, and HbA1c levels. Using low-dose aspirin (100 mg/d) was 
a risk factor for aspirin-resistant status in both diabetic patients and overall 
study group. 
17) Antoni et al (2007)48 conducted a study on use of aspirin for primary and 
secondary prevention of cardiovascular disease in diabetic patients in an 
ambulatory care. The study concluded that treatment with aspirinis 
underused for primary prevention in patients with diabetes mellitus in 
primary care.  
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18) Jack et al (2017)49 conducted a study on primary prevention of 
cardiovascular disease. The study revealed that the burden of 
cardiovascular disease can be ameliorated by careful risk reduction and, as 
such, primary prevention is an important priority for all developers of 
health policy.  
19) S. Fateh et al (2005) 50conducted a study on prevalence of aspirin 
resistance in patients with type two diabetes. The study concluded that the 
major finding of the present study is that a substantial number of patients 
with type 2 diabetes are resistant (21.5%) or semi-resistant (16.9%) to 
chronic aspirin treatment. Aspirin resistance may be poorer clinical long 
term prognosis in a substantial subgroup of patients with type2 DM. 
20) Waanger et al (2001)51 performed a study on diabetes mellitus and 
cardiovascular disease. The study revealed that diabetes is associated with 
poor prognosis of cardiovascular disease and with high short term long 
term mortaliy. 
21) Christo et al (2001)52 conducted a study on differences in expression of 
cardiovascular risk factors among type two DM Patients of different age. 
The study revealed that hyperglycemia, dyslipidemia, and lowgrade 
inflammation are present in different age groups of T2DM patients studied 
and reconfirm previous observations on the role of these conditions in 
predisposing the development of CVD in these patients.  
22) Christina et al (2007)53 performed a study on type II diabetes mellitus and 
cardiovascular risk factors: The study reveals that that insulin resistance, 
the metabolic syndrome and type II DM are inextricably linked with CVD, 
as apparent from the increased levels of CVD morbidity and mortality and 
from the presence of a complex array of CVD risk markers. Targeting 
multiple markers of CVD risk hopefully offers the best chance of 
improving CVD outcomes. 
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SCOPE OF STUDY 
         Worldwide, approximately 200 million people currently have type II 
diabetes mellitus (DM), a prevalence that has been predicted to increase to 366 
million by 2030. Rates of cardiovascular disease (CVD) mortality and morbidity 
are particularly high in this population, representing a significant cost for health 
care systems. Type II DM patients generally carry a number of risk factors for 
CVD, including hyperglycemia, abnormal lipid profiles, alterations in 
inflammatory mediators and coagulation/thrombolytic parameters, as well as other 
‘nontraditional’ risk factors, many of which may be closely associated with insulin 
resistance. Therefore, successful management of CVD associated with diabetes 
represents a major challenge to the clinicians.55 
              An effective way of tackling this problem is to detect the associated risk 
factors and to target treatment toward their improvement. Targeting 
hyperglycemia alone does not reduce the excess risk in diabetes, highlighting the 
need for aggressive treatment of other risk factors. Although the current use of 
statin therapy is effective at reducing low-density lipoprotein cholesterol, residual 
risk remains for other independent lipid and nonlipid factors. 56     
 Diabetes is endemic in India. The International Diabetes Federation has 
estimated that India currently has more than 65 million people with type 2 
diabetes and the numbers are poised to double in the next 20 years. It has been 
reported that the prevalence of diabetes among urban participants in India is 
among the highest in the world and comparable to the high prevalence countries 
of West Asia and the Pacific. In India it has been reported that 60–80% of patients 
with diabetes die of cardiovascular events. 
                  According to the WHO, “non-communicable diseases, mainly 
cardiovascular diseases, cancers, chronic respiratory diseases and diabetes, are the 
main cause of death and disability in the world, representing 63% of deaths. 80% 
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of cases of premature cardiovascular diseases and stroke, 80% of type 2 diabetes 
and 40% of cancers could be avoided by eating healthily, doing regular physical 
exercise and not smoking.” According to the International Diabetes Federation “it 
is estimated that around 285 million people throughout the world, i.e. 6.6% of 
people in the 20 – 79 year age group, will develop diabetes in 2010, of which 70% 
live in low or middle-income countries. These figures will probably increase by 
over 50% over the next 20 years unless prevention programmes are put into place.       
 
.Antiplatelet therapy is a cornerstone of cardiovascular medicine. Aspirin 
and clopidogrel have emerged as critical therapies in the treatment of 
cardiovascular disease. Despite their efficacy, patients on these medications 
continue to suffer complications. Millions of patients are currently on low-dose 
antiplatelet therapy but it is unknown how many of these patients are under-
treated or on the wrong medication. Aspirin and clopidogrel resistance are 
emerging clinical entities with potentially severe consequences such as recurrent 
myocardial infarction, stroke, or death. The mechanism of resistance remains 
incompletely defined, but there are specific clinical, cellular, and genetic factors 
that influence therapeutic failure. These factors range from physicians who fail to 
prescribe these medications despite appropriate indications to polymorphisms of 
platelet membrane glycoproteins. Rapid and accurate diagnosis of antiplatelet 
resistance also remains an issue as new bedside tests are developed. By 
understanding the mechanism of therapeutic failure and by improving the 
diagnosis of this clinical entity, a new era of individualized antiplatelet therapy 
may arise with routine measurements of platelet activity in the same way that 
cholesterol, blood pressure, and blood sugar are followed, thus improving the care 
for millions of people. 
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        Inter individual variability of platelet aggregation in response to these 
antiplatelet agents may be an explanation for some of these recurrent events, and 
small trials have linked “aspirin and/or clopidogrel resistance”, as measured by 
platelet function tests, to adverse events. Systematically reviewed all available 
evidence on the prevalence of aspirin/clopidogrel resistance, their possible risk 
factors and their association with clinical outcomes. After analyzing the data on 
different laboratory methods found that aspirin/clopidogrel resistance seems to be 
associated with poor clinical outcomes and there is currently no standardized or 
widely accepted definition of clopidogrel resistance. Therefore, conclude that 
specific treatment recommendations are not established for patients who exhibit 
high platelet reactivity during aspirin/clopidogrel therapy or who have poor 
platelet inhibition by clopidogrel. 
  
                The study will attempt to categorize each patients depending on the risk 
and non-risk case of CVD in type 2 DM. The AHD guidelines are followed in risk 
cases of CVD to understand drug utilization ,duration of treatment possibility of 
resistance with anticoagulant therapy.57 
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                              OBJECTIVE OF THE STUDY  
 
• To evaluate drug utilization pattern in diabetic patients 
 Assess the risk factors associated with CVD in type 2 diabetic patients 
• Evaluate the primary and secondary management of CVD in type 2 DM  
• Assess the therapy of CVD prevention in type II DM patients. 
• Evaluate  the drug interaction in the prescription  
Plan of the Study 
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PLAN OF THE STUDY 
 
 The proposed study was planned and carried out as per the given plan and 
it was designed as given below. 
 
STUDY SITE  :    Cardiology and General medicine department. 
STUDY DESIGN: Prospective-Observational study. 
STUDY PERIOD: 10 months (November2016- August2017) 
PHASE I  
 Selection of study site and department. 
 Literature survey 
 Preparation of Protocol 
 Obtaining consent from the hospital authorities. 
 
PHASE II  
 Designing of structured data entry format. 
 Data collection using data entry format 
  Evaluation of collected data of the patients 
 Categorization of patients 
 Assessment of CVD risk by Framingham Risk Score 
 Evaluation of drug utilization pattern 
 Assessment of CVD therapy 
 Evaluate drug interaction in the prescription. 
PHASE III  
 Interpretation and data analysis. 
 Preparation of the project report and submission to the study department. 
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METHODOLOGY 
STUDY SITE: 
 The proposed work entitled “Study on cardiovascular risk factors and 
its management in type II DM patients” was carried out in a 750 bedded multi-
speaciality hospital located at Coimbatore. The hospital is unique and it is well 
known for its services to people who come from various parts of country. The 
institution excels in diverse specialities like General Medicine, General Surgery, 
Obestrics and Gynecology, Peadiatrics and Neonatalogy, Orthopeadics, 
Psychiatry, Neurology, Radiology, Cardiology, Cardiothoracic surgery, 
Pulmunology and Critical care, Gastroenterology, Urology, Nephrology, E.N.T, 
Opthomology, Oncology, Dentistry, Plastic surgery and department of physical 
rehabilitation. The hospital has well-staffed Pharmacy and Drug Information 
Centre. 
 The hospital is well equipped with modern diagnostic facilities like CT 
scan, MRI scan, US, digital subtraction angiography, ECG, treadmill, color 
Doppler etc. The hospital also have twelve well equipped Hi-tech operation 
thetres, Intensive Care Units, Intensive Cardiac Units, Intensive Pulmunory Care 
unit, Neonatal Intensive Care unit, Catheterization laboratory performing 
diagnostic cardiac catheterization, balloon valvuloplasty, coronary stening, kidney 
transplantation unit with hemodialysis machines, assisted reproductive technology 
centre, 24hours microbiological and pathological services, round the clock 
casuality and pharmacy services etc. 
DEPARTMENT SELECTED FOR THE STUDY IN THE HOSPITAL: 
 The department selected for the study is General Medicine and 
Cardiology. The reason for the selection of these departments were the prevalence 
of variety of cases. The Department of Pharmacy Practice provides services to 
these departments and a good co-operation from medical team added up to the 
reason for selecting these departments for conducting the study. 
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CONSENT FROM HOSPITAL AUTHORITIES: 
 Every project work carried out in the hospital by the Pharmacy Practice 
department students has to be approved by the Dean of the hospital and should be 
informed to all the physicians and other healthcare professionals of the hospital. A 
protocol of the study which includes the objectives, methodology etc was 
submitted to the Dean of the hospital. The authorization from the Dean was 
procured through his letter [SRH/EC.9-7/2017-18 dated 25th FEBRUARY 2017] 
and the same is attached for the reference in the [Annexure I]. The study was 
conducted with the expert guidance of junior and senior physicians of the study 
departments. The authority was permitted to utilize the hospital facilities to make 
a follow up of the cases, in the selected departments. All the health care 
professionals were well  informed through Dean’s official circular. 
LITERATURE SURVEY: 
  Extensive literature survey was being performed regarding the rationality 
of fixed dose combinations. The necessary information are collected and well 
documented. The literatures supporting the study were gathered from various 
sources such as: 
 American Journal of Cardiology 
 International Journal of Research in Pharmacology and 
 Pharmacotherapeutics 
 New England Journal of Medicines  
 European Journal of Clinical Pharmacology 
 Indian Journal of Hospital Pharmacy and some of the websites including 
 www.medscape.com, www.pubmed.com and databases such as 
 Micromedex. 
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DATA ENTRY FORM: 
A separate data entry form were designed and the format contains the 
details such as name, age, sex, height, weight, IP. No, date of admission, date of 
discharge, reason for admission, past medical history, past medication history and 
social history. Provision was given in the format for entry of details like blood 
sugar levels,  liver function test, renal function test, electrolytes, urine 
examination, lipid profile, diagnosis, drug chart, risk factors, 10 year 
cardiovascular risk calculation, ADR monitoring chart, Drug interaction chart and 
any interventions.(Annexure-2) 
 
DATA COLLECTION: 
Ward Round Participation  
 A regular ward round was carried out. Each patient’s demographics were 
recorded including date, age, weight, date of admission and discharge, past 
medical and medication histories were also obtained. 
                           
PATIENT SELECTION: 
Inclusion criteria: 
 Patients above age of 18 years either the sex ,who have been diagnosed to 
 have diabetes with or without CVD. 
 Patients who are willing to participate in the study. 
 
Exclusion criteria:  
 Patients below age of 18 years, pregnant women,  critically ill and  patients 
 not willing to participate excluded from the study 
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PATIENT INFORMATION FORM  
A patient information form was prepared to inform the patient or the care givers 
about the purpose and necessity of the study.The patients were assured that the 
confidentiality will strictly maintained. The model of information form is given 
in( Annexure 3) for reference.  
 
PATIENT CONSENT FORM 
 A patient consent form has been prepared and written consent was 
obtained from the patient or from the care givers. The format contains details like 
address, date, place, provision for signature of the patient or caregivers, 
investigator and supervisor. The same is given in the [Annexure 4] for reference. 
 
DATA ANALYSIS  
 The data from the cases were evaluated. The study population were 
categorized into CVD and non CVD category. Assessment of cardiovascular risk 
was calculated for non CVD patients using Framingham risk score.  Evaluvation  
of CVD preventive therapy has been carried out. 
 
REPORT SUBMISSION      
 The report on the study results were prepared and the same was submitted 
to the study department for necessary action  on future therapy for a safe and 
effective treatment. 
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RESULTS AND DISCUSSION 
 The proposed work entitled “Study on Cardiovascular Risk Factors and 
its Management in Type II DM patients” was a carried out in a 750 bedded 
multispecialty hospital, in the department of General medicine and Cardiology. 
The study was carried out during November 2016 to October2017.  
 A total of 103 patients were included in the study based on the inclusion 
and exclusion criteria, among them 64 (62%) were males and 39 (37.86%) were 
females. [Table No- 1].The age categorization was done in which, it was found 
that 7 (3.8%) belonged to the age group of 30-40 followed by 9 (8.73) in the age 
group of 40-50 , 28 (27.1%) in the age group of 50-60, and 59 (57.2%) of them 
were ޓ60 years. [Table No-2 ]  
ASSESSMENT OF PREVALENCE OF CARDIOVASCULAR DISEASES 
 Among the study population 73(70.87%) patients were found to be 
suffering from CVD and 30 (29.1%) were non CVD patients. [Table No- 3].The 
various types of CVD suffered by patients were analyzed , it was found that 
majority of them were diagnosed with IHD 30 (42%), followed by CAD 24 
(32.8%), Stroke 6 (8.21%) and CCF 7 (9.58%), and ACS 6(5.82%), . [Table No- 
4].This result reveals that IHD and CAD are the most common CVDs among 
study population in Type II DM patients. A similar study conducted Anurag S 
Lekar et al (2013) revealed that IHD is the major disease suffered by their study 
population. 
CATEGORIZATION OF DRUG PRESCRIBED FOR DM  
 The study population was prescribed with various classes of anti-diabetic 
medications. The drug utilization pattern reveals that majority of the study 
population has received insulin therapy for  56 (54.36%)patients followed by 
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thiazolidinediones 15.5 (14.56%), sulfonyl ureas 14 (13.59%) and biguanides 7 
(6.79%). (Table No- 5) 
DRUGS PRESCRIBED FOR CVD PATIENTS  
 The CVD agents utilized by the study population was analyzed which has 
been classified into 11 categories. A total of 315 drugs were prescribed. Among 
which, the most frequently prescribed drug class was anticoagulants 132 
(41.90%), followed by dyslipidemic agents 56 (17.77%), antianginals 31 (9.84%), 
diuretics 30 (9.52%), beta adrenergic blockers 16 (5.07%), cardiotonic agents  
14 (4.44%), calcium channel blockers 10 (3.17%), angiotensin antagonists  
8 (2.53%), antiarrhythmics 7 (2.22%) and alpha + beta adrenergic blockers  
6 (1.90%). (Table No -6 ).A similar study conducted by  Ittaman SV et al (2014) 
reported that anticoagulant therapy is well-accepted as an agent for the prevention 
of cardiovascular events. 
RISK FACTORS ASSOCIATED WITH NON CVD PATIENTS 
 Risk factors were categorized for non CVD patients and the results 
revealed that DM and gender were the major risk factors. This was followed by 
age, hypertension & cholesterol for 27(90%) patients, 21(70%) & 21(70%) 
respectively. Other risk factors found in the study population were family history, 
obesity for 18 (60%) and 9 (30%) patients respectively. (Table No -7).  A study 
conducted by Maguy Chiha (2012) revealed that Diabetes mellitus is associated 
with an increased risk of cardiovascular death and a higher incidence of CVD. 
 
 
FRAMINGHAM RISK SCORE:  
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 The Framingham risk score is a scale used to assess the 10 year future 
CVD risk percentage for the non-CVD patients. The patients belonging to non-
CVD group were assessed using Framingham risk scale to determine the 
cardiovascular risk percentage. The results revealed that 19 (63.33%) patients 
have ޓ20% future CVD risk followed by ,8 (26.66%) patients with 10-20% of 
future CVD risk and about 3 (10%) patients with ޒ10% of future CVD risk. 
[Table No: 8].  
PATIENTS ON PRIMARY AND SECONDARY PREVENTION OF CVD  
 Among the study population, 30 (29.1%) patients were provided with 
primary CVD prevention and 73 (70.87%) patients received secondary CVD 
prevention therapy. (Table No-9). Aspirin and clopidogrel were the drugs 
prescribed for primary prevention for about 20 patients (66%) and 10 patients 
(33%) respectively.(Table No- 10) Drugs given for secondary prevention includes 
atorvastatin for 57 (78.08%) patients , followed by clopidogrel for 54 (73.97%), 
aspirin for 40 (54.79%), atenolol for 16 (21.97%), isosorbide mononitrate for 15 
(20.54%) and enalapril for 5 (6.84%) patients. (Table No- 11). 
EVALUATION OF DRUGS INCREASING CVD RISK 
 Certain non CVD drugs on prolonged use can increase risk of 
cardiovascular disease. The non CVD drugs prescribed for the study population 
which possess cardiovascular risk was identified .The result revealed that 11 
(10.61%)patients were prescribed with diclofenac  5(4.85%) patients were 
prescribed with glimepride and1(0.970%) patient on  terbutaline are at increased 
risk of CVD.(Table No-12)  A similar study conducted by Schellack N, B (2014) 
reported that NSAIDS, sulfonylureas and terbutaline carry the risk of serious 
cardiovascular adverse effects . 
DRUG INTERACTION 
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 In the present study around 168 drug –drug interaction were identified 
among  which 4 (2.38%) prescription were major interaction 36(26.4%) were 
moderate interaction 128 (76.19%) were on minor interactions.(Table No-13)  
The moderate drug interaction involving clopidogrel and pantoprazole was found 
to be maximal in current study.(Table No- 14) 
 Diabetes mellitus is associated with an increased risk of cardiovascular 
death and a higher incidence of CVD. Though aspirin and clopidogrel had proven 
benefits in cardiovascular events, their prolonged use can develop resistance in 
patients. Significant number of type 2 diabetic patients are resistant to aspirin 
therapy. Therefore aspirin resistance should be evaluated by point of care testing 
and should be recognized in diabetic patients who are treated for primary and 
secondary prevention. Efficient and affordable laboratory tests (bleeding time, 
optical aggregometry, platelet aggregation ratio) with standard techniques should 
be used to correlate the results with clinical outcomes. 
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TABLE NO:1  GENDER CATEGORIZATION 
 
Sex No of patients(  n=103) Percentage (%) 
Male 64 62.2 
Female 39 37.8 
 
 
 
 
 
 
 
 
FIGURE NO 1  :  GENDER 
CATEGORIZATION
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TABLE-2     AGE DISTRIBUTION 
Age in years No of patients (n=103 ) Percentage(%) 
30-40 7 3.8 
40-50 9 8.7 
50-60 28 27.1 
Above60 59 57.4 
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TABLE- 3  ASSESSMENT OF PREVALAENCE OF CVD 
Prevalence No of patients (n=103) Percentage (%) 
CVD patients 73 70.8 
Non CVD patients 30 29.2 
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TABLE 4 CATEGORIZATION OF CVD PATIENTS 
Types of CVD No of patients (n=73) Percentage( %) 
CCF 7 9.5 
STROKE 6 8.5 
CAD 24 32.8 
ACS 6 8.2 
IHD 30 42.0 
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Antidiabetic Drugs No of patients (n=103) Percentage(%) 
Insulin Therapy 56 54.3 
Bigunides 7 6.8 
Thiazolidinediones 15 14.5 
Sulfonyl Urea 14 13.5 
Combination drugs 11 10.6 
 
 
 
 
TABLE-6 DRUGS PRESCRIBED FOR CVD PATIENTS 
Drugs for CVD No prescriptions Percentage( %) 
54.3
6.8
14.5 13.5
10.6
0
10
20
30
40
50
60
P
E
R
C
E
N
T
A
G
E
CATEGORISATION OF ANTIDIABETIC DRUGS PRESCRIBED 
FIGURE NO-5 CATEGORISATION OF DRUG 
PRESCRIBED FOR DM   
Results & Discussion 
 
 
 
Study on Cardiovascular Risk Factors and its  
Management in Type 2 Diabetic Patients  48 
(n=315) 
Anticoagulants 132 41.9 
Dyslipidemic agents 56 17.7 
Calcium channel blockers 10 3.1 
Beta adrenergic blockers 16 5.0 
Alpha+ beta adrenergic 
blockers 
6 1.9 
ACE inhibitors 5 1.5 
Angiotensinogen 
antagonist 
8 2.5 
Antianginal drugs 31 9.8 
Antiarrthmic drugs 7 2.2 
Cardiotonic agents 14 4.4 
Diuretics 30 9.5 
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Risk factors No of  patients (n=30) Percentage (%) 
Age 27 90 
Sex 30 100 
DM 30 100 
Obesity 9 30 
Hypertension 21 70 
Physical inactivity 17 56.6 
Family history 18 60 
Smoker 9 30 
High blood 
cholesterol levels 
21 70 
 
 
TABLE-8   FRAMINGHAM RISK SCORE 
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Risk percentage 
(For Future 10 Year) No of patients( n=30) Percentage(%) 
>20 19 63.3 
10-20 8 26.6 
<10 3 10.1 
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Primary prevention 30 29.2 
Secondary prevention 73 70.8 
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Aspirin 20 66.6 
Clopidogrel  10 33.4 
 
 
 
 
 
 
 
 
TABLE NO 11 DRUGS PRESCRIBED FOR SECONDARY PREVENTION  
Drugs for secondary 
prevention  ( n=73)  
No patients Percentage(%) 
Aspirin 40 54.7 
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Atenolol  16 21.9 
Atorvastatins 57 78 
Enapril 5 6.8 
Clopidogrel 54 73.9 
Isosorbidate mononitrate 15 20.5 
 
 
 
 
 
 
TABLE 12 -  EVALUATION OF DRUGS INCREASING CVD RISK 
Drugs No of prescription (n=103) Percentage (%) 
Diclofenac 11 10.6 
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Glimepride 5 4.8 
Terbutaline 1 0.97 
 
 
 
 
 
 
TABLE-13  DRUG INTERACTIONS 
Drug interaction No of prescription (n=168) Percentage (%) 
Major 4 2.3 
Moderate 36 21.4 
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TABLE 14 DRUG INTERACTIONS 
Drugs Effects 
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Drugs Effects 
No 
prescriptions 
(n=168) 
Severity 
Clopidogrel+Pantoprazole 
Pantoprazole 
reducing effect of 
clopidogrel in 
preventing heart 
attack and stroke. 
39 Moderate 
Clopidogrel+heparin Both increase 
anticoagulations 21 Minor 
Aspirin +clopidogrel Increase toxicity 21 Moderate 
Clopidogrel+torsemide 
Clopidogrel 
increase effect of 
torsemide 
4 Minor 
Heparin+acetaminophen May increase effect 
of heparin 6 Minor 
Heparin+aspirin May increase 
anticoagulation 29 Moderate 
Heparin+ramipril 
May increase levels 
of potassium in the 
body 
1 Moderate 
Aspirin +metoprolol 
May increase levals 
of potassium in the 
body 
4 Minor 
Aspirin+telmisartan May increase serum potassium levels. 3 Moderate 
Aspirin+ketorlac Either increase toxicity of other 1 Major 
Aspirin +glimipride Aspirin increase 
effect of glimepride 1 Moderate 
Aspirin +nebivilol 
Both increase 
serum potassium 
levels 
3 Moderate 
Aspirin+carvedilol Aspirin decrease 
effect of carvedilol 4 Moderate 
Aspirin+sotalol 
Both increase 
serum potassium 
levels 
2 Moderate 
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Drugs Effects 
No 
prescriptions 
(n=168) 
Severity 
Aspirin+torsemide 
Aspirin increase 
and torsemide 
decrease serum 
potassium levels 
2 Moderate 
Aspirin+spirolactone 
Both increase 
serum potassium 
levels 
5 Moderate 
Aspirin+torsemide 
Aspirin increase 
and torsemide 
decrease serum 
potassium levels 
2 Moderate 
Telmisartan +metoprolol 
Both increase 
serum potassium 
levels 
5 Moderate 
Telmisartan+atorvastatins 
Telmisartan 
increase toxicity of 
atorvastatins 
1 Moderate 
Telmisartan+torsemide 
Telmisartan 
increase torsemide 
decrease serum 
potassium level 
2 Moderate 
Atorvastains+azithromycin 
Atorvastatins will 
increase level or 
effect of 
azithromycine 
1 Moderate 
Clonidine+metoprolol Increase toxicity of 
one another 1 Moderate 
Clonidine+insulin Clonidine decrease 
effect of insulin 1 Minor 
Azithromycin+sotalol Both may increase QT intervel 1 Moderate 
Azithromycin+ondansetrol Both increase QT intervels 3 Major 
Calcium accete+amlodipine 
Calcium acetate 
decrease effect of 
amlodipine 
1 Moderate 
Ramipril+spirolactone May be risk of hyperkalemia 4 Moderate 
Results & Discussion 
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Drugs Effects 
No 
prescriptions 
(n=168) 
Severity 
Ranolazine+metoprolol Ranolazine increase levels of metoprolol 2 Moderate 
Atorvastatins+spirolactone 
Spirolactone will 
increase levels of 
atorvastains 
5 Moderate 
Atorvastatins+prednisolone 
Prednislone will 
decrese levels of 
atorvastatins 
2 Moderate 
Metformin+insulin May increase risk 
of hypoglycemia 1 Moderate 
Budesonide+insulin 
Budesonide 
decrease effect of 
insulin 
2 Moderate 
Budesonide+atorvastatins 
Atorvastatins 
increase effect of 
budesonide 
2 Moderate 
Budesonide+pantoprazole 
Pantoprazole 
decrease effect 
budesonide by 
increase gastric pH 
levels 
1 Moderate 
Budesonide+heparin 
May chance of 
decrease 
anticoagulant effect 
2 Moderate 
Budesonide+clopidogrel 
Budesonide will 
increase effect of 
clopidogrel 
3 Moderate 
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CONCLUSION 
   Current study results reveals patient with Type II Diabetes are either 
having one of the CVD or they are at high risk of developing CVD in future. 
Therefore, CVD prevention in such patients is mandatory. The CVD prevention 
therapy is long term management that may even continue for life time depending 
on the patient condition. Aspirin and Clopidogrel are the most widely used drugs 
in CVD prevention. Aspirin and Clopidogrel are having high chance of forming 
resistance in Type 2 Diabetic patients. Hence the use of aspirin and clopidogrel 
necessitates monitoring the effectiveness of these drugs CVD prevention. Clinical 
pharmacist has a great responsibility in such monitoring and preventing such 
resistance that occurs with the use of aspirin and clopidogrel. The results also 
implicates there is a high prevalence rate of CVD in Type 2 diabetic patients. The 
incidence of CVD would have reduced if proper patient education and 
management are implemented. It is essential to follow guidelines such as ADA 
and AHA continuous monitoring by Clinical Pharmacist for  reducing rate of 
CVD in Type 2 Diabetic patients. Hence the study concluded that implementation 
of pharmaceutical care activities in Type 2 diabetic patients will ensure safe and 
efficient CVD prevention therapy. 
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FUTURE OUTLOOK 
  
 The diabetic patients are increasing globally and the management of 
diabetes has significantly improved. Being chronic disorder diabetes has many 
complications which makes prevention and management of these complications 
highly challenging. The most typical complication of diabetes is occurrence of 
CVD. The numbers of CVD patients among type2-diabetics are drastically 
increasing, due to complicated task of CVD prevention. The guidelines for CVD 
prevention in Diabetics must be regularly updated. Currently there are no Indian 
guidelines on CVD prevention and management of type 2 diabetic patients, hence 
there is a need for developing guidelines for Indian population for an effective 
CVD prevention and management in Type 2 Diabetes. Resistance formation by 
the long term use of aspirin and clopidogrel warrants the need for continuous 
monitoring these drugs for their safety and efficacy. Hence future studies can 
focus on identifying the causes and prevention of resistance for aspirin and 
clopidogrel. The monitoring parameters and guidelines for aspirin and clopidogrel 
use in diabetics can be developed, which will be beneficial for an effective CVD 
prevention in patients with diabetics. 
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